Business Wire | February 08, 2018
Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will be presenting at the LEERINK Partners 7th Annual Global Healthcare Summit. The presentation will take place on Thursday, February 15, at 10:00 a.m. EST in New York City.
Business Wire | January 04, 2018
Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference.
Business Wire | January 02, 2018
Ultra-Sensitive Biomarker Detection System is now available in a compact size with increased workflow flexibility
BusinessWire | December 11, 2017
Quanterix Corporation (NASDAQ:QTRX), a company with a next generation, ultra-sensitive digital platform that advances precision health, today announced the closing of its initial public offering of 4,916,480 shares of common stock at a public offering price of $15.00 per share, including 641,280…
Nasdaq | December 07, 2017
Quanterix Corporation (Nasdaq:QTRX), a company with a next generation, ultra-sensitive digital platform that advances precision health, will visit the Nasdaq MarketSite in Times Square.
Business Wire | December 06, 2017
Today Quanterix announced the pricing of its initial public offering of 4,275,200 shares of its common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $64,128,000. In addition, Quanterix has granted the underwriters a 30-day option to purchase up to 641,280…
Business Wire | November 10, 2017
New technology unlocks ultra-sensitive biomarker detection with the potential to advance the diagnosis and treatment of neurological diseases
CAMBRIDGE, MA – September 2, 2009 – Quanterix Corporation, the leader in single molecule detection, announced today that David Okrongly, Ph.D. has been appointed Chief Executive Officer and a member of the company’s Board of Directors. Dr. Okrongly replaces co-founder and interim CEO, Nicholas…
Quanterix Discovers Link Between Heart Attack–induced Hypoxia and Suspected Alzheimer’s Disease Pathway
CAMBRIDGE, MA – April 12, 2011 – Quanterix Corporation, enabling a new generation of diagnostics based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that significant elevations in blood levels of amyloid beta (Aβ) 42 peptide, a component of the plaques that are a…
Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
CAMBRIDGE, MA – December 1, 2011 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today that it has been awarded a one year $250,155 contract from the Department of Homeland…